Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The development of an effective HIV-1 vaccine continues to pose a formidable challenge. While traditional approaches of live-attenuated and inactivated vaccines are either too dangerous or inefficient, modern and safer subunit vaccines are still in their infancy and struggle to cope with various aspects of HIV-1 biology, including the enormous variability of HIV-1. Three simple prophylactic candidate vaccine strategies have now been tested in human efficacy trials, with only a very marginal and yet to be confirmed success in the most recent one. Thus, HIV-1 immunological control, which may require induction of both broadly neutralizing antibodies and T cells capable of controlling multiple clades and escape variants. At protective levels, an increase in subunit vaccine design complexity is required. I argue that, by analogy to antiretroviral treatment, even a relatively complex vaccine may not only serve to prove the concept, but can be successfully deployed in countries with limited resources and infrastructure. © 2010 Future Medicine Ltd.

Original publication




Journal article


HIV Therapy

Publication Date





543 - 552